Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Lonafarnib in Leukemia
NCT00034684Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2001
- Primary completion
- Oct 2003
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of lonafarnib in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), sponsored by Merck & Co.. Started Jul 2001; status: completed.
02
Drugs
lonafarnib
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00034684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034684.